

## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com http://www.wjgnet.com

## ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 20440

Title: Hepatitis C Eradication: A long way to go

Reviewer's code: 00052899 Reviewer's country: China Science editor: Ya-Juan Ma

**Date sent for review: 2015-06-06 14:45** 

Date reviewed: 2015-06-18 19:29

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
[ ] Grade A: Excellent	[ ] Grade A: Priority publishing	Google Search:	[ ] Accept
[ ] Grade B: Very good	[ Y] Grade B: Minor language	[ ] The same title	[ ] High priority for
[Y] Grade C: Good	polishing	[ ] Duplicate publication	publication
[ ] Grade D: Fair	[ ] Grade C: A great deal of	[ ] Plagiarism	[ ] Rejection
[ ] Grade E: Poor	language polishing	[ Y ] No	[ Y] Minor revision
	[ ] Grade D: Rejected	BPG Search:	[ ] Major revision
		[ ] The same title	
		[ ] Duplicate publication	
		[ ] Plagiarism	
		[ Y ] No	

## **COMMENTS TO AUTHORS**

In this article, the author summarized the status in quo of HCV infection and treatment, particularly in low and middle income countries. The author concluded that the control of HCV pandemic required financial investment, political will and support from medical, pharmaceutical and civil organizations. The manuscript is brief and concise. However, there remain some concerns in the current article. The author calculated the cost of sofosbuvir which is the mainstay of interferon-free combination therapy. Nevertheless, interferon and ribavirin are still the first line drugs for HCV treatment in many countries. The cost of them should also be taken into consideration. Moreover, considering the long treatment periodicity of HCV, methods for improving patient's compliance are needed. There are several typographical errors which should be corrected by a native English speaker.